Request availability and a quotation for your required quantity and destination.
| Product | Abrocitinib 100 mg - Cibinqo |
|---|---|
| Categories | Skin Care |
| Availability | Confirmed on enquiry |
Product listing is not a recommendation to use this medicine. Prescription and destination requirements apply where relevant.
Product categories: Skin Care
Primary clinical indication: Atopic dermatitis (eczema)
Cibinqo contains abrocitinib, an oral Janus kinase 1 (JAK1) inhibitor. Its FDA-approved indication is refractory moderate-to-severe atopic dermatitis in eligible people 12 years and older, when other systemic therapies have not adequately controlled disease or are inadvisable. It is not an approved hair-growth medicine.
Abrocitinib reduces inflammatory signaling through JAK1. A dermatologist may consider it for specific patients with difficult-to-control atopic dermatitis after assessing previous treatment and clinical risks.
Cibinqo has boxed warnings concerning serious infections, mortality, cancer, major cardiovascular events and thrombosis. Screening for tuberculosis and other infections, blood tests, vaccination review and ongoing monitoring may be necessary. Never begin without a specialist.
Nausea, headache, acne, herpes infections and changes in laboratory values can occur. Seek urgent care for chest pain, breathing difficulty, limb swelling, or serious infection symptoms.
Tugain 5 topical minoxidil · Avodart dutasteride. These are distinct treatments, not interchangeable products.
FDA 2026: Cibinqo prescribing information
Its approved use is for qualifying atopic dermatitis, not hair growth.
The U.S. label includes eligible patients aged 12 and older; other criteria also apply.
It inhibits JAK1-mediated inflammatory signaling.
No. It is an oral JAK1 inhibitor.
A prescriber may request infection screening, blood counts and other monitoring tests.
Yes. Serious infections are among its boxed warnings.
Certain combinations are not recommended; a specialist should assess other treatments.
Acne is a reported adverse effect.
Fever with illness, breathing difficulty, chest pain or unusual limb swelling warrant prompt evaluation.
Pregnancy requires specialist review and adherence to current product labeling.
Cureiva provides educational product information and handles lawful enquiries subject to prescriptions, product verification and destination-country rules. This is not individual medical advice or a claim of clinician sign-off. Updated October 2026.